Premium Nahrungsergänzungsmittel | artgerecht

tNGS: Targeted Next Generation Sequencing Explained

tNGS (Targeted Next Generation Sequencing) is a modern molecular diagnostic method enabling focused genetic analysis, widely used in infectious disease and oncology.

Regular tips about health Regular tips about health

Things worth knowing about "tNGS"

tNGS (Targeted Next Generation Sequencing) is a modern molecular diagnostic method enabling focused genetic analysis, widely used in infectious disease and oncology.

What is tNGS?

tNGS (Targeted Next Generation Sequencing) is a focused form of high-throughput sequencing in which specifically selected genomic regions or pathogen populations are analyzed. Unlike whole genome sequencing (WGS), tNGS concentrates on predefined target regions, enabling faster, more cost-effective, and clinically relevant results. The method is applied in both infectious disease diagnostics (pathogen detection, resistance profiling) and oncology (tumor genomics, mutation analysis).

How It Works

In tNGS, genetic material (DNA or RNA) is extracted from a patient sample. Specific probes or primers are then used to enrich only the relevant genomic segments, which are subsequently sequenced. The resulting sequence data are analyzed bioinformatically and compared against reference databases.

Sample types: Blood, tissue, sputum, bronchoalveolar lavage, cerebrospinal fluid, or other body fluids
Target regions: Resistance genes, virulence factors, oncologically relevant mutations, pathogenic organisms
Analysis: Bioinformatic pipeline with database matching (e.g., NCBI, CARD, ClinVar)

Areas of Application

Infectious Disease

In infectious disease medicine, tNGS enables the simultaneous identification of multiple pathogens and the determination of antibiotic resistance directly from patient samples, without the need for pathogen culture. This is especially valuable for difficult-to-culture or rare pathogens and for immunocompromised patients.

Detection of bacteria, viruses, fungi, and parasites
Resistome analysis (e.g., beta-lactamases, MRSA, MDR tuberculosis)
Outbreak surveillance

Oncology

In oncology, tNGS is used for tumor panels to detect clinically relevant somatic mutations, gene fusions, or copy number alterations in cancer-related genes. This supports targeted therapy selection (precision medicine).

Detection of therapy-relevant mutations (e.g., EGFR, KRAS, BRCA1/2)
Liquid biopsy (circulating tumor DNA from blood)
Minimal residual disease (MRD) monitoring

Advantages Over Conventional Methods

Higher sensitivity: Detection of very low pathogen loads or rare mutations
Multiplexing: Simultaneous analysis of many target sequences in a single run
Speed: Results often available within 24–48 hours
Broad pathogen spectrum: No prior suspicion needed in pathogen diagnostics

Limitations and Challenges

Despite its many advantages, tNGS also has limitations. Interpretation of bioinformatic data requires specialized expertise, and the quality of results depends heavily on sample quality and the completeness of the reference databases used. Issues related to data privacy and clinical validation are also important considerations.

Dependence on database quality and completeness
No information on pathogens outside the target regions
High demands on bioinformatics infrastructure
Regulatory and ethical aspects of genetic findings

Clinical Significance

tNGS is gaining increasing importance in modern medicine, particularly in the diagnosis of complex infections in intensive care units, in guiding anti-infective therapies, and in personalized cancer treatment. Guidelines from various medical societies increasingly recommend tNGS as a complement to or replacement for classical diagnostic methods.

References

Gu W, Miller S, Chiu CY. Clinical Metagenomic Next-Generation Sequencing for Pathogen Detection. Annual Review of Pathology: Mechanisms of Disease. 2019;14:319-338.
Jennings LJ, et al. Principles and methods of next-generation sequencing (NGS) and its clinical application. Journal of Molecular Diagnostics. 2017;19(2):174-186.
Mosele F, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Annals of Oncology. 2020;31(11):1491-1505.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.